Nothing Special   »   [go: up one dir, main page]

WO2023098798A8 - 用于治疗非小细胞肺癌的药物组合 - Google Patents

用于治疗非小细胞肺癌的药物组合 Download PDF

Info

Publication number
WO2023098798A8
WO2023098798A8 PCT/CN2022/135865 CN2022135865W WO2023098798A8 WO 2023098798 A8 WO2023098798 A8 WO 2023098798A8 CN 2022135865 W CN2022135865 W CN 2022135865W WO 2023098798 A8 WO2023098798 A8 WO 2023098798A8
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
small cell
cell lung
treating non
drug combination
Prior art date
Application number
PCT/CN2022/135865
Other languages
English (en)
French (fr)
Other versions
WO2023098798A1 (zh
WO2023098798A9 (zh
Inventor
申丽丽
张喜全
王训强
于鼎
刘璐
Original Assignee
正大天晴药业集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正大天晴药业集团股份有限公司 filed Critical 正大天晴药业集团股份有限公司
Priority to CN202280074057.9A priority Critical patent/CN118201963A/zh
Priority to EP22900602.8A priority patent/EP4442710A1/en
Publication of WO2023098798A1 publication Critical patent/WO2023098798A1/zh
Publication of WO2023098798A9 publication Critical patent/WO2023098798A9/zh
Publication of WO2023098798A8 publication Critical patent/WO2023098798A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供用于治疗非小细胞肺癌药物组合，其包括抗PD-L1抗体和化疗药物，以及任选的安罗替尼或其药学上可接受的盐；还提供了所述药物组合在制备用于治疗非小细胞肺癌的药物中的用途。
PCT/CN2022/135865 2021-12-01 2022-12-01 用于治疗非小细胞肺癌的药物组合 WO2023098798A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202280074057.9A CN118201963A (zh) 2021-12-01 2022-12-01 用于治疗非小细胞肺癌的药物组合
EP22900602.8A EP4442710A1 (en) 2021-12-01 2022-12-01 Drug combination for treating non-small cell lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111452473.1 2021-12-01
CN202111452473 2021-12-01

Publications (3)

Publication Number Publication Date
WO2023098798A1 WO2023098798A1 (zh) 2023-06-08
WO2023098798A9 WO2023098798A9 (zh) 2023-09-14
WO2023098798A8 true WO2023098798A8 (zh) 2023-11-02

Family

ID=86611515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/135865 WO2023098798A1 (zh) 2021-12-01 2022-12-01 用于治疗非小细胞肺癌的药物组合

Country Status (3)

Country Link
EP (1) EP4442710A1 (zh)
CN (1) CN118201963A (zh)
WO (1) WO2023098798A1 (zh)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015301126B2 (en) 2014-08-05 2021-03-11 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
WO2020156500A1 (zh) * 2019-01-31 2020-08-06 正大天晴药业集团股份有限公司 抗pd-l1抗体治疗头颈癌的用途
WO2020187152A1 (zh) * 2019-03-15 2020-09-24 正大天晴药业集团股份有限公司 治疗小细胞肺癌的联用药物组合物
CN118267469A (zh) * 2019-06-10 2024-07-02 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
CN119424632A (zh) * 2019-07-03 2025-02-14 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物
CN113018429A (zh) * 2019-12-24 2021-06-25 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合

Also Published As

Publication number Publication date
WO2023098798A1 (zh) 2023-06-08
EP4442710A1 (en) 2024-10-09
WO2023098798A9 (zh) 2023-09-14
CN118201963A (zh) 2024-06-14

Similar Documents

Publication Publication Date Title
Kawato et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
Kanzawa et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
Emmenegger et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide
Ferreri et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
WO2021226208A3 (en) Heteroaromatic macrocyclic ether chemotherapeutic agents
EP4424375A3 (en) Antineoplastic combinations of neratinib and capecitabine
WO2017176744A8 (en) Methods of treating pediatric cancers
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
WO2021062085A8 (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4378530A3 (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
MX2024002822A (es) Composicion farmaceutica y uso de la misma.
WO2022221834A3 (en) Method for treating lung cancer and non-small cell lung cancer
MX2022007643A (es) Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5.
WO2023098798A8 (zh) 用于治疗非小细胞肺癌的药物组合
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
Okamoto et al. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non–small-cell lung cancer
Hainsworth Rituximab as first-line systemic therapy for patients with low-grade lymphoma
Testolin et al. Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma: A phase II study
Tanaka et al. Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro
EP4161522A4 (en) PYRAZOLO [4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS
Comella et al. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil iv bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma
Yamada et al. Multicenter phase II study of Nedaplatin and Irinotecan for patients with squamous cell carcinoma of the lung: Thoracic oncology research group 0910
AU2020240797A8 (en) Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22900602

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280074057.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12024551202

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022900602

Country of ref document: EP

Effective date: 20240701